Cached score snapshot
US.RVTY · Revvity
110分制 56.5/110;5D動能v2 4/50;排序分 60.5/160
Score breakdown
觀望
Score and price trend
Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.
Move the mouse over the chart lines to inspect readings.
- Main score
- 5D momentum v2
- Candlestick
- Historical projection
- Score turn
- Setup grade
| Model | Median | P25/P75 | 歷史相似情境上漲比例 | Down5 | Actual / compare |
|---|---|---|---|---|---|
| Rolling DOE best | +0.97% | -0.92% / +3.24% | 60% | 5% | Actual +1.92% · vs median +0.95% · inside 25-75 band |
| 30D observation | +3.60% | -2.16% / +12.41% | 67.5% | 17.5% | Actual outcome pending · 1 / 30 bars observed |
| Historical projection 10D n=160 | +0.51% | -1.31% / +2.85% | 55.6% | 7.5% | Actual outcome pending · 1 / 10 bars observed |
歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。
2026-07-16 → 2026-11-19 · 177 archived points · 6 Improving turn signal · 5 Deteriorating signal
Summary
score_with_momentum_v2 = main score + 5D momentum v2
Rolling setup rating
Setup quality, historical edge, and risk are combined into a rolling S/A/B/C/D/F grade for this snapshot date.
Score turn monitor
Has the score quality changed?
Run more market refreshes to build enough archived points for a turn check.
Signals
技術信號 18.4 · 資金流 13.2 · 5D動能v2 4
INSTITUTIONAL_DATA_OPTIONAL: Institutional ownership unavailable; neutral money-flow treatment used. FMP_INSTITUTIONAL_FAILED: FMP HTTP 402
Audit trace
Full calculation detail
Calculation detail · 8 sections
Market inputs
Metrics snapshot
110-point main rating
基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10
基本面 — 2.4/5 · 較差
Sub-items
資金流 — 13.2/20 · 一般
Sub-items
institutional
details
warning
市場環境 — 10.8/15 · 良好
Sub-items
vix
details
trend
details
qqq
spy
催化劑 — 2/20 · 較差
Sub-items
catalyst
details
風險管理 — 5.7/10 · 較差
Sub-items
position
details
stopLevels
strength_details
diversification
details
技術信號 — 18.4/30 · 一般
Sub-items
vcpPayload
vcp_metrics
情緒分析 — 4/10 · 較差
Sub-items
sentiment
details
sentimentData
Dimension contribution
5D momentum v2 breakdown
Cursor_18.25 5D momentum v2 0-50
Risk management
position
details
stopLevels
strength_details
diversification
details
Calculation audit log
基本面分析總分: 2.4/5分 資金流分析總分: 13.2/20分 市場環境分析總分: 10.8/15分 催化劑分析: 2/20分 風險管理總分: 5.7/10分 技術信號分析總分: 18.4/30分 情緒分析: 4/10分 共振率(僅顯示不加分): 0%
Technical indicators
adx
atr
cci
cmf
kdj
mfi
obv
rsi
sar
ma50
macd
vwap
volume
derived
ma_cross
bollinger
rsi_short
macd_short
volume_ratio
Raw calculation JSON
{
"risk": {
"level": "Elevated",
"reason": "risk management score >= 5/10",
"position": {
"score": 1.1,
"details": {
"atrPct": 4.052116193480547,
"turnoverUsdM": 221.681904,
"liquidityPoints": 0.4,
"volatilityPoints": 0.7
}
},
"rrPoints": 1.4,
"stopLevels": {
"symbol": "US.RVTY",
"rr_range": "1:1.0-1:2.5",
"risk_profile": "中等",
"stop_loss_price": 139.8286,
"strength_details": {
"ma_score": 1.5,
"atr_score": 1,
"rsi_score": 3,
"macd_score": 1.5,
"volume_score": 1
},
"market_adjustment": 1,
"risk_reward_ratio": 1,
"stop_loss_percent": 8.1,
"take_profit_price": 164.8511,
"target_multiplier": 1.9,
"technical_strength": 1.63,
"take_profit_percent": 8.3
},
"positionPoints": 1.1,
"stopLossPoints": 1.2,
"diversification": {
"score": 2,
"details": {
"method": "sector concentration proxy; no portfolio holdings used",
"sector": "Health Care",
"concentratedSectorPenalty": 0
}
},
"riskRewardRatio": 1.2,
"stopLossPercent": 8.104232386961094,
"diversificationPoints": 2
},
"total": {
"max": 160,
"result": 60.5,
"formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
"baseScore": 56.5,
"modelVersion": "cursor_18_27_news_v2_160",
"momentum5dScore": 4
},
"market": {
"ma20": 146.6695,
"ma50": 131.2764,
"close": 152.16,
"prevClose": 153.6,
"avgVolume20": 2353670,
"volumeRatio": 0.62,
"changePercent": -0.94
},
"sources": {
"catalyst": "finnhub_news_keyword_model",
"sentiment": "finnhub_news_keyword_model",
"fundamentals": "fmp_stable",
"institutional": null,
"marketContext": "twelvedata+fred"
},
"barCount": 60,
"momentum": {
"max": 50,
"result": 4,
"details": {
"ret_5d": 0.020797008195317268,
"max_score": 50,
"max_total": 50,
"raw_total": 4,
"vcp_bonus": 0,
"vol_ratio": 0.6204789131291192,
"ret_points": 4,
"vol_points": 0,
"range_ratio": 0.9304163656972562,
"volat_points": 0,
"day_range_pct": 0.0371977523659306,
"model_version": "cursor_18_27_news_v2_160",
"available_bars": 30,
"breakout_points": 0,
"partial_history": false,
"pullback_points": 0,
"breakout_vol_bonus": 0,
"first_breakout_20d": false,
"return_window_days": 5,
"first_breakout_bonus": 0,
"breakout_quality_points": 0
},
"formula": "Cursor_18.25 5D momentum v2 0-50",
"modelVersion": "cursor_18_27_news_v2_160"
},
"scoreMax": 110,
"composite": {
"max": 160,
"result": 60.5,
"formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
"weights": [
{
"raw": 2.4,
"label": "基本面",
"weight": "5/110",
"normalized": 48,
"contribution": 2.4
},
{
"raw": 13.2,
"label": "資金流",
"weight": "20/110",
"normalized": 66,
"contribution": 13.2
},
{
"raw": 10.8,
"label": "市場環境",
"weight": "15/110",
"normalized": 72,
"contribution": 10.8
},
{
"raw": 2,
"label": "催化劑",
"weight": "20/110",
"normalized": 10,
"contribution": 2
},
{
"raw": 5.7,
"label": "風險管理",
"weight": "10/110",
"normalized": 57,
"contribution": 5.7
},
{
"raw": 18.4,
"label": "技術信號",
"weight": "30/110",
"normalized": 61.33,
"contribution": 18.4
},
{
"raw": 4,
"label": "情緒分析",
"weight": "10/110",
"normalized": 40,
"contribution": 4
}
],
"modelVersion": "cursor_18_27_news_v2_160"
},
"momentumMax": 50,
"scoreStatus": "checked",
"standard110": {
"rating": "觀望",
"result": 56.5,
"details": [
"基本面分析總分: 2.4/5分",
"資金流分析總分: 13.2/20分",
"市場環境分析總分: 10.8/15分",
"催化劑分析: 2/20分",
"風險管理總分: 5.7/10分",
"技術信號分析總分: 18.4/30分",
"情緒分析: 4/10分",
"共振率(僅顯示不加分): 0%"
],
"formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
"dimensionScores": {
"催化劑": 2,
"基本面": 2.4,
"資金流": 13.2,
"市場環境": 10.8,
"情緒分析": 4,
"技術信號": 18.4,
"風險管理": 5.7
},
"dimensionDetails": {
"催化劑": {
"max": 20,
"grade": "較差",
"items": {
"catalyst": {
"score": 2,
"details": {
"source": "finnhub_news_keyword_model",
"articleCount": 8,
"catalystCount": 0
}
},
"catalystPoints": 2
}
},
"基本面": {
"max": 5,
"grade": "較差",
"items": {
"pbPoints": 0.5,
"pePoints": 0.2,
"epsPoints": 0,
"roePoints": 0,
"debtPoints": 0.5,
"marginPoints": 0,
"turnoverUsdM": 221.681904,
"volumePoints": 0.5,
"revenuePoints": 0,
"dividendPoints": 0.3,
"marketCapPoints": 0.4
},
"source": "fmp_stable"
},
"資金流": {
"max": 20,
"grade": "一般",
"items": {
"cmfPoints": 2.4,
"mfiPoints": 2.4,
"obvPoints": 2.4,
"vwapPoints": 4,
"institutional": {
"score": 2,
"details": {
"source": "optional-neutral",
"warning": {
"code": "INSTITUTIONAL_DATA_OPTIONAL",
"symbol": "US.RVTY",
"message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
},
"optional": true,
"holderCount": null,
"holderPoints": 2,
"top10ShareRatio": null,
"concentrationPenalty": 0
}
},
"institutionPoints": 2
}
},
"市場環境": {
"max": 15,
"grade": "良好",
"items": {
"vix": {
"score": 2.4,
"details": {
"source": "twelvedata+fred",
"vixClose": 15.08
}
},
"trend": {
"score": 4,
"details": {
"qqq": {
"ma20": 735.7219992500001,
"ma50": 723.1690000399999,
"name": "QQQ",
"close": 747.58002,
"points": 2
},
"spy": {
"ma20": 767.26299675,
"ma50": 766.83679764,
"name": "SPY",
"close": 773.92999,
"points": 2
},
"source": "twelvedata+fred"
}
},
"atrPct": 4.052116193480547,
"atrPoints": 2,
"cciPoints": 2.4,
"vixPoints": 2.4,
"marketTrendPoints": 4
}
},
"情緒分析": {
"max": 10,
"grade": "較差",
"items": {
"sentiment": {
"score": 4,
"details": {
"source": "finnhub_news_keyword_model",
"articleCount": 8,
"negativeHits": 0,
"positiveHits": 2,
"sentimentScoreRaw": 0.6
}
},
"sentimentData": {
"raw": [
{
"id": 142592011,
"url": "https://finnhub.io/api/news?id=1354c9a3ac86acca82d61b1988ec9d31e1f0743e2810cf95605e1c46072883de",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
"category": "company",
"datetime": 1790953202,
"headline": "Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?"
},
{
"id": 142499577,
"url": "https://finnhub.io/api/news?id=ff4832de7ba97e9983ed854de2a013c27c693bf0523e62c4715efc273d08445c",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
"category": "company",
"datetime": 1790700002,
"headline": "Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?"
},
{
"id": 142423965,
"url": "https://finnhub.io/api/news?id=a9ff4d3ba263b75cc7992bb9bb5763803e41a2e984ca6e0e139ac9d5b22bbd62",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.",
"category": "company",
"datetime": 1790341740,
"headline": "RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection"
},
{
"id": 142350477,
"url": "https://finnhub.io/api/news?id=cb58c8c8f2b541bcd7567cd8dc86f2dd0998a2a24d9e4da3258e8a9c57c37605",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity (RVTY) has drawn fresh attention after recent share price gains, with the stock up about 15% over the past month and roughly 36% over the past 3 months. Over the past year, Revvity has shifted from lagging long term returns, with a 5 year total shareholder return down 16.56%, to strong recent momentum. The 1 year total shareholder return reached 67.67%, and the 90 day share price return came in at 35.67%. Scan beyond Revvity's sharp rebound and explore other hand-picked opportunities...",
"category": "company",
"datetime": 1790129530,
"headline": "Why Revvity (RVTY) Is Getting Attention Today"
},
{
"id": 142188758,
"url": "https://finnhub.io/api/news?id=03b1bbe1a346d39ced2120c20af628767c205f491c25a175a480c992424683c9",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
"category": "company",
"datetime": 1789550040,
"headline": "Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?"
},
{
"id": 142162217,
"url": "https://finnhub.io/api/news?id=c9e230170d179b85b200d044ccc0f27596b9851ed1649e5e94f0dc70a6ee1f7d",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Revvity (NYSE:RVTY) and its peers.",
"category": "company",
"datetime": 1789479331,
"headline": "Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks"
},
{
"id": 142164499,
"url": "https://finnhub.io/api/news?id=a187851a3b32d0f518cf6a22cdf7cb457662bd37fcebf1db3d2d732edf49b488",
"image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"source": "SeekingAlpha",
"related": "RVTY",
"summary": "Revvity, Inc. (RVTY) 2026 Global Healthcare Conference September 15, 2026 9:05 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor...",
"category": "company",
"datetime": 1789473097,
"headline": "Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript"
},
{
"id": 142138505,
"url": "https://finnhub.io/api/news?id=69174abc8d26e7ed40432acacd43de7ef7c90e09eac260583ae38c53c0592293",
"image": "",
"source": "SeekingAlpha",
"related": "RVTY",
"summary": "",
"category": "company",
"datetime": 1789385497,
"headline": "Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
}
],
"raw_source": [
{
"id": 142728921,
"url": "https://finnhub.io/api/news?id=0dd7d1b383dd91d4ef55e272b4d0e25c1c563ddef68dfa481dcf459a3f0016fa",
"image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
"source": "ChartMill",
"related": "RVTY",
"summary": "Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Thursday and stay ahead of the market trends.",
"category": "company",
"datetime": 1791470101,
"headline": "Which S&P500 stocks are gapping on Thursday?"
},
{
"id": 142693767,
"url": "https://finnhub.io/api/news?id=b58fc40ae5e598dea8cde16f52126f564cf1c2ee3879ed84982d201a4a9383d5",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "281-Page Report Tracks Post-Pandemic Research Growth Across Pharma, Research and Industry/Cosmetic Users as 3D Assays, Automation and Immuno-oncology Reshape Drug DiscoveryDublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- \"Cell-Based Assay & High Content Screening Market 2025-2029 - Forecasts by User and Product, with Executive and Consultant Guides\" has been added to ResearchAndMarkets.com's offering. Research and Markets has published Cell-Based Assay & High Content Screening Market 2025-2029 - Foreca",
"category": "company",
"datetime": 1791373560,
"headline": "Cell-Based Assay & High Content Screening Market Report Reveals Why Technology Is Outpacing the Market, Profiling Thermo Fisher, Roche, Sartorius, Revvity & 50 Other Key Players"
},
{
"id": 142728288,
"url": "https://finnhub.io/api/news?id=8d9b36bda25cc3dae2a96a864dce6dd65b5b0892657a362c9ee1d7be1a2a3179",
"image": "",
"source": "Benzinga",
"related": "RVTY",
"summary": "Barclays analyst Luke Sergott maintains Revvity (NYSE:RVTY) with a Equal-Weight and raises the price target from $115 to $160.",
"category": "company",
"datetime": 1791372093,
"headline": "Barclays Maintains Equal-Weight on Revvity, Raises Price Target to $160"
},
{
"id": 142697475,
"url": "https://finnhub.io/api/news?id=5293fb6cb9cd661ac9f7d6788a377cca7b6432efc60ab2ab7a30c515d13e581b",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity will release its third-quarter earnings next month, and analysts anticipate a high single-digit bottom-line growth.",
"category": "company",
"datetime": 1791363263,
"headline": "Revvity Earnings Preview: What to Expect"
},
{
"id": 142694619,
"url": "https://finnhub.io/api/news?id=1ca703b7fad07089c730aef2b5ff799b55d0fa3971297d860aacc4957655612f",
"image": "",
"source": "Benzinga",
"related": "RVTY",
"summary": "William Blair analyst Matt Larew initiates coverage on Revvity (NYSE:RVTY) with a Outperform rating.",
"category": "company",
"datetime": 1791303270,
"headline": "William Blair Initiates Coverage On Revvity with Outperform Rating"
},
{
"id": 142694620,
"url": "https://finnhub.io/api/news?id=947600016a722f37a30f498b8ac2a29d931f9e0e2fe0b9640f578c701ecc477d",
"image": "https://cdn.benzinga.com/files/images/story/2026/10/06/Revvity-Inc.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "RVTY",
"summary": "William Blair initiates Revvity (RVTY) at Outperform, citing AI tailwinds, life sciences recovery, and potential 20%+ stock upside.",
"category": "company",
"datetime": 1791298272,
"headline": "Revvity Nears 52-Week High, but This Analyst Thinks Stock Can Climb Another 20%"
},
{
"id": 142663473,
"url": "https://finnhub.io/api/news?id=77771d918fee3d8e31646d64918184c9a6dda8db8f26fbdf378ad0829d4dcbf5",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "WALTHAM, Mass., October 06, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.",
"category": "company",
"datetime": 1791288000,
"headline": "Revvity to Host Investor Day"
},
{
"id": 142592011,
"url": "https://finnhub.io/api/news?id=1354c9a3ac86acca82d61b1988ec9d31e1f0743e2810cf95605e1c46072883de",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
"category": "company",
"datetime": 1790953202,
"headline": "Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?"
},
{
"id": 142588838,
"url": "https://finnhub.io/api/news?id=20f528af1e1b120c026025dfda2cdf1c613fc223627e530195c33ed1dffc0e4d",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "WALTHAM, Mass., October 02, 2026--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.",
"category": "company",
"datetime": 1790942400,
"headline": "Revvity to Hold Earnings Call on November 3, 2026"
},
{
"id": 142521568,
"url": "https://finnhub.io/api/news?id=8796fb4f75396d1828b23a3b1b8c40d67fff4a675fd7b4ca8feac4460090c598",
"image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
"source": "ChartMill",
"related": "RVTY",
"summary": "Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.",
"category": "company",
"datetime": 1790787900,
"headline": "Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session."
},
{
"id": 142499577,
"url": "https://finnhub.io/api/news?id=ff4832de7ba97e9983ed854de2a013c27c693bf0523e62c4715efc273d08445c",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
"category": "company",
"datetime": 1790700002,
"headline": "Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?"
},
{
"id": 142498306,
"url": "https://finnhub.io/api/news?id=b99b47066bf1db0d53f43dfd46ad34ae8002db612643d2fa307c56c3e05fdaf9",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.",
"category": "company",
"datetime": 1790687520,
"headline": "Here's Why You Should Retain Revvity Stock in Your Portfolio for Now"
},
{
"id": 142463267,
"url": "https://finnhub.io/api/news?id=fc9a13a952922c8e6a07e852b9dc7e22771cf21ad57968453bc3b6669662339b",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
"category": "company",
"datetime": 1790586156,
"headline": "1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds"
},
{
"id": 142423965,
"url": "https://finnhub.io/api/news?id=a9ff4d3ba263b75cc7992bb9bb5763803e41a2e984ca6e0e139ac9d5b22bbd62",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.",
"category": "company",
"datetime": 1790341740,
"headline": "RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection"
},
{
"id": 142423581,
"url": "https://finnhub.io/api/news?id=6c773b4b4fd56046165f9f939d6d09120e989435edcb977079470afccf6c629d",
"image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_2.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "RVTY",
"summary": "Revvity (NYSE:RVTY) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below.\nThis content is powered by Benzinga APIs. For",
"category": "company",
"datetime": 1790313777,
"headline": "Full Transcript: Revvity Q2 2026 Earnings Call"
},
{
"id": 142385877,
"url": "https://finnhub.io/api/news?id=0a10ab9058f099ea9dd8fed3a27d11f516b03ecf689b3ca7ecb544bfc4264f7b",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9",
"category": "company",
"datetime": 1790280084,
"headline": "Sector Update: Healthcare Stocks Advance Late Afternoon"
},
{
"id": 142385317,
"url": "https://finnhub.io/api/news?id=f6f2a26b9f5647288b5da04eda91284fe1679478b8b585e97013ed1ba637efe8",
"image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
"source": "ChartMill",
"related": "RVTY",
"summary": "Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.",
"category": "company",
"datetime": 1790276701,
"headline": "Discover which S&P500 stocks are making waves on Thursday."
},
{
"id": 142423582,
"url": "https://finnhub.io/api/news?id=dbcf2dda78e5857b21e4ffb41aceed01250ceb475132a6bb612a945f2768a415",
"image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "RVTY",
"summary": "Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.72%. Currently, Revvity has a market capitalization of $16.82 billion.",
"category": "company",
"datetime": 1790271929,
"headline": "Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years"
},
{
"id": 142384739,
"url": "https://finnhub.io/api/news?id=064fca65c12d5a6a144b02ffa288fa39c2b8d29421fbe717d8ae80b17cdacb6f",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "All three major US stock indexes fell in late-morning trading Thursday amid uncertainty in the Middl",
"category": "company",
"datetime": 1790265971,
"headline": "Top Midday Stories: Oracle's Data Center Delay; People Withdraws MGM Offer; Revvity's New Diabetes Test"
},
{
"id": 142374834,
"url": "https://finnhub.io/api/news?id=57a218c79f8db9c5829dc0b25bcf5d3d5d2d104a3cb88128bac31f9d804f3aa9",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "WALTHAM, Mass., September 24, 2026--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear.",
"category": "company",
"datetime": 1790251200,
"headline": "Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes"
},
{
"id": 142379627,
"url": "https://finnhub.io/api/news?id=6f5fae7103718fad61d71f792ffe7fcab9e945543672660195665d850dedefdd",
"image": "",
"source": "Benzinga",
"related": "RVTY",
"summary": "Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that",
"category": "company",
"datetime": 1790237027,
"headline": "Revvity Rolls Out GSP T1D 3plex Kit"
},
{
"id": 142363351,
"url": "https://finnhub.io/api/news?id=08e21debb549e8d7bd2c4b8c5893e45852ed71ecc7711b290ef91bf21303ffcf",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity has notably outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.",
"category": "company",
"datetime": 1790159593,
"headline": "Is Revvity Stock Outperforming the Dow?"
},
{
"id": 142350477,
"url": "https://finnhub.io/api/news?id=cb58c8c8f2b541bcd7567cd8dc86f2dd0998a2a24d9e4da3258e8a9c57c37605",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity (RVTY) has drawn fresh attention after recent share price gains, with the stock up about 15% over the past month and roughly 36% over the past 3 months. Over the past year, Revvity has shifted from lagging long term returns, with a 5 year total shareholder return down 16.56%, to strong recent momentum. The 1 year total shareholder return reached 67.67%, and the 90 day share price return came in at 35.67%. Scan beyond Revvity's sharp rebound and explore other hand-picked opportunities...",
"category": "company",
"datetime": 1790129530,
"headline": "Why Revvity (RVTY) Is Getting Attention Today"
},
{
"id": 142328474,
"url": "https://finnhub.io/api/news?id=85efb7d8043da2785c44589fe07e464369b52343ea3a62c863b956ea862cb220",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"Label-Free Detection - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Label-Free Detection was valued at US$553 Million in 2024 and is projected to reach US$847 Million by 2030, growing at a CAGR of 7.4",
"category": "company",
"datetime": 1790065560,
"headline": "Capitalize on the Label-Free Detection Market Shift: Track How Danaher, Sartorius, Agilent, Bruker and Revvity Are Disrupting R&D ROI and Reshaping Global Revenue Through 2030"
},
{
"id": 142328487,
"url": "https://finnhub.io/api/news?id=293df837bbb17c71cf269b411ac0010b830920bae67dc70e20edcee04009550a",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"High Content Screening (HCS) - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for High Content Screening (HCS) was valued at US$1.3 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing",
"category": "company",
"datetime": 1790065140,
"headline": "Capitalize on High Content Screening Disruption: Decode How Thermo Fisher Scientific, Danaher, Revvity, and Yokogawa Are Reshaping Global R&D ROI and Revenue"
},
{
"id": 142269870,
"url": "https://finnhub.io/api/news?id=97da2091fb37a98868cc4df2c623e9c31db2fd3283341dda1e7fd6b0739faf09",
"image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149954800/image_2149954800.jpg?io=getty-c-w1536",
"source": "SeekingAlpha",
"related": "RVTY",
"summary": "U.S. stocks closed the week mixed as Treasury yields rose amid a Fed rate hike, and fears of AI development grew. Read more about this week's top events on Wall Street.",
"category": "company",
"datetime": 1789800247,
"headline": "What Moved Markets This Week"
},
{
"id": 142270772,
"url": "https://finnhub.io/api/news?id=2fbac1a765a47bf212e99e40ad93c0b49a5ff423030f1a4db735d13f67e98fb2",
"image": "https://cdn.benzinga.com/files/images/story/2026/09/18/Diesel-Prices-Cross-6.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "RVTY",
"summary": "The Fed hiked for the first time since 2023; the 10-year yield touched 5.04%, and record diesel prices hit truckers and automakers.",
"category": "company",
"datetime": 1789747909,
"headline": "Fed Raises Rates, Yields Hit 2007 Highs as Fuel Costs Set Records: This Week On Wall Street"
},
{
"id": 142249608,
"url": "https://finnhub.io/api/news?id=713a37af216447ec3bd78a404d516aab7a7639f9e3cf8a77d99b3839d2ffcb44",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.",
"category": "company",
"datetime": 1789719440,
"headline": "1 Momentum Stock with Promising Prospects and 2 Facing Headwinds"
},
{
"id": 142198959,
"url": "https://finnhub.io/api/news?id=568783958075196b65740530debea12cb32f6534984a1b55719ef4f7c7471b7c",
"image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
"source": "ChartMill",
"related": "RVTY",
"summary": "Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.",
"category": "company",
"datetime": 1789585501,
"headline": "Explore the top gainers and losers within the S&P500 index in today's session."
},
{
"id": 142188758,
"url": "https://finnhub.io/api/news?id=03b1bbe1a346d39ced2120c20af628767c205f491c25a175a480c992424683c9",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
"category": "company",
"datetime": 1789550040,
"headline": "Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?"
},
{
"id": 142167113,
"url": "https://finnhub.io/api/news?id=b9533ba462e02bc4cdd69ebe009cce3b112c1338397a301218653d5b059ea426",
"image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
"source": "ChartMill",
"related": "RVTY",
"summary": "Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.",
"category": "company",
"datetime": 1789499101,
"headline": "Discover which S&P500 stocks are making waves on Tuesday."
},
{
"id": 142162217,
"url": "https://finnhub.io/api/news?id=c9e230170d179b85b200d044ccc0f27596b9851ed1649e5e94f0dc70a6ee1f7d",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Revvity (NYSE:RVTY) and its peers.",
"category": "company",
"datetime": 1789479331,
"headline": "Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks"
},
{
"id": 142194774,
"url": "https://finnhub.io/api/news?id=d1cab808ccf45cf13f1263e44cacc1adc587155103fca3659b6bbe4aa4db95f1",
"image": "https://cdn.benzinga.com/files/images/story/2026/09/15/Stock-Market-Graph-Crashing-Down--Wall-S.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "RVTY",
"summary": "The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.",
"category": "company",
"datetime": 1789478829,
"headline": "10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today"
},
{
"id": 142165183,
"url": "https://finnhub.io/api/news?id=41ebfd4b80544d2c7c619a56a61cee031e3049ed69310da56b5dd1c7a7151515",
"image": "https://image.cnbcfm.com/api/v1/image/108326254-1782318177071-gettyimages-2213364616-img_9901.jpeg?v=1782318352&w=1920&h=1080",
"source": "CNBC",
"related": "RVTY",
"summary": "These are the stocks posting the largest moves midday.",
"category": "company",
"datetime": 1789473808,
"headline": "Stocks making the biggest moves midday: Skyworks Solutions, Axon, Dave & Buster's, Revvity & more"
},
{
"id": 142164499,
"url": "https://finnhub.io/api/news?id=a187851a3b32d0f518cf6a22cdf7cb457662bd37fcebf1db3d2d732edf49b488",
"image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"source": "SeekingAlpha",
"related": "RVTY",
"summary": "Revvity, Inc. (RVTY) 2026 Global Healthcare Conference September 15, 2026 9:05 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor...",
"category": "company",
"datetime": 1789473097,
"headline": "Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript"
},
{
"id": 142195468,
"url": "https://finnhub.io/api/news?id=84be75a7fa25fb4e6b70806a85064079868a4c59df9eb73aed8b3ebb3fbe2245",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical validation across Nu.Q NETs, Nu.Q Cancer, and Capture-Seq. Management has simultaneously decreased operating expenses, which were reduced in the most recent",
"category": "company",
"datetime": 1789402620,
"headline": "VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space."
},
{
"id": 142139504,
"url": "https://finnhub.io/api/news?id=892ee473a89448e463e9ebabbdd3627fdd3c2e2cad825c716923497669bcd3f3",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.",
"category": "company",
"datetime": 1789399410,
"headline": "3 Healthcare Stocks That Fall Short"
},
{
"id": 142138505,
"url": "https://finnhub.io/api/news?id=69174abc8d26e7ed40432acacd43de7ef7c90e09eac260583ae38c53c0592293",
"image": "",
"source": "SeekingAlpha",
"related": "RVTY",
"summary": "",
"category": "company",
"datetime": 1789385497,
"headline": "Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
},
{
"id": 142087303,
"url": "https://finnhub.io/api/news?id=ccd73376aab39d765a0ae9080eecae78d1cc12a45b23ff5dbdcee5c0d0633f93",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.",
"category": "company",
"datetime": 1789139940,
"headline": "Revvity to Acquire Human Cell Design to Boost Metabolic Discovery"
},
{
"id": 142025419,
"url": "https://finnhub.io/api/news?id=26ba77f1d5d5d1d933db3ca05680140c3536502285a122c8a8b36cdf9f7d1322",
"image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
"source": "ChartMill",
"related": "RVTY",
"summary": "Let's have a look at the S&P500 gap up and gap down stocks in today's session.",
"category": "company",
"datetime": 1788964501,
"headline": "These S&P500 stocks are gapping in today's session"
},
{
"id": 142026577,
"url": "https://finnhub.io/api/news?id=cb092d0177c73ef991e01bd2f9b86bc6b770d0cc8355a7025df5d92b2dc0bbcc",
"image": "",
"source": "SeekingAlpha",
"related": "RVTY",
"summary": "",
"category": "company",
"datetime": 1788958626,
"headline": "Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript"
},
{
"id": 142007727,
"url": "https://finnhub.io/api/news?id=c1105d1e4e608643a2f4b83f95153adcb96bcc32f5073d0146317266dabca956",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "WALTHAM, Mass., September 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, includin",
"category": "company",
"datetime": 1788948000,
"headline": "Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery"
},
{
"id": 142026253,
"url": "https://finnhub.io/api/news?id=14a165ee3da6cf1e87cced8f93e5010791421eec4a891b5f0776077838aedbf3",
"image": "",
"source": "Benzinga",
"related": "RVTY",
"summary": "UBS analyst Doug Schenkel assumes Revvity (NYSE:RVTY) with a Neutral rating and raises Price Target to $140.",
"category": "company",
"datetime": 1788947825,
"headline": "UBS Assumes Revvity at Neutral, Raises Price Target to $140"
},
{
"id": 142026254,
"url": "https://finnhub.io/api/news?id=afa5a4ecb2479e8eee511d8473093253608857e03a715a73a0bd02872012e9a4",
"image": "https://cdn.benzinga.com/files/images/story/2026/09/09/Revvity-Inc.jpg?width=2048&height=1536",
"source": "Benzinga",
"related": "RVTY",
"summary": "Revvity buys Human Cell Design to expand diabetes and GLP-1 drug discovery tech. Acquisition expected to close in Q4 2026.",
"category": "company",
"datetime": 1788946529,
"headline": "Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition"
},
{
"id": 142026255,
"url": "https://finnhub.io/api/news?id=c0e3abf1a20772b3a6ef5ac36a02a5c40065dd69d9c3e39cefaa9ae53e03f69c",
"image": "",
"source": "Benzinga",
"related": "RVTY",
"summary": " The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other",
"category": "company",
"datetime": 1788934162,
"headline": "Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And Preclinical Research Solutions For Diabetes, Obesity And Other Metabolic Diseases"
},
{
"id": 141950366,
"url": "https://finnhub.io/api/news?id=9ffbefa46ae6a3e4ca32751051e8d41fdf4e5c7ea74772461a6e2e856ea0ded6",
"image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
"source": "Yahoo",
"related": "RVTY",
"summary": "500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031\" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro",
"category": "company",
"datetime": 1788878940,
"headline": "Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others"
}
],
"data_source": "finnhub_news_keyword_model",
"article_count": 8,
"negative_hits": 0,
"positive_hits": 2,
"recomputed_at_score": true,
"sentiment_score_raw": 0.6,
"source_article_count": 46,
"discarded_article_count": 37
},
"sentimentPoints": 4
}
},
"技術信號": {
"max": 30,
"raw": 18.4,
"grade": "一般",
"items": {
"bbPoints": 3,
"adxPoints": 3,
"sarPoints": 2.4000000000000004,
"vcpPoints": 0.9,
"macdPoints": 2.4,
"vcpPayload": {
"vcp_pass": false,
"vcp_score": 0.9,
"vcp_reason": "站上MA50;升放量(近10日2日);Ready=N;Confirm=N",
"vcp_metrics": {
"up_days": 6,
"vol_ref": 2159530,
"down_days": 3,
"vcp_ready": false,
"above_ma50": true,
"avg_vol_10": 2221880,
"avg_vol_20": 2348025,
"avg_vol_30": 2159530,
"range_pct_10": 0.16075190588853847,
"range_pct_20": 0.2980415352260778,
"range_pct_30": 0.2980415352260778,
"up_expand_ok": true,
"lookback_used": 59,
"near_20d_high": false,
"contraction_ok": false,
"down_shrink_ok": false,
"up_expand_days": 2,
"breakout_20d_ok": false,
"vol_ratio_10_30": 1.028872023079096,
"dist_to_20d_high": 0.08475187969924815,
"down_shrink_days": 1,
"breakout_level_20d": 166.25,
"vcp_breakout_confirm": false,
"contraction_ratio_10_30": 0.5393607497243663
},
"vcp_name_en": "Volatility Contraction Pattern",
"vcp_name_zh": "波動收縮形態",
"vol_contraction": false
},
"kdjAdxPoints": 0.5,
"rsiKdjPoints": 2.4,
"volumeWeight": 2,
"maCrossPoints": 1.6,
"shortRsiPoints": 0.4,
"shortMacdPoints": 0.4,
"volConfirmPoints": 1,
"volumePointsTechnical": 0.4
}
},
"風險管理": {
"max": 10,
"grade": "較差",
"items": {
"position": {
"score": 1.1,
"details": {
"atrPct": 4.052116193480547,
"turnoverUsdM": 221.681904,
"liquidityPoints": 0.4,
"volatilityPoints": 0.7
}
},
"rrPoints": 1.4,
"stopLevels": {
"symbol": "US.RVTY",
"rr_range": "1:1.0-1:2.5",
"risk_profile": "中等",
"stop_loss_price": 139.8286,
"strength_details": {
"ma_score": 1.5,
"atr_score": 1,
"rsi_score": 3,
"macd_score": 1.5,
"volume_score": 1
},
"market_adjustment": 1,
"risk_reward_ratio": 1,
"stop_loss_percent": 8.1,
"take_profit_price": 164.8511,
"target_multiplier": 1.9,
"technical_strength": 1.63,
"take_profit_percent": 8.3
},
"positionPoints": 1.1,
"stopLossPoints": 1.2,
"diversification": {
"score": 2,
"details": {
"method": "sector concentration proxy; no portfolio holdings used",
"sector": "Health Care",
"concentratedSectorPenalty": 0
}
},
"riskRewardRatio": 1.2,
"stopLossPercent": 8.104232386961094,
"diversificationPoints": 2
}
}
}
},
"modelVersion": "cursor_18_27_news_v2_160",
"providerErrors": [],
"rankingScoreMax": 160,
"dataCompleteness": {
"complete": true,
"missingFields": [],
"optionalInputs": [
"institutionalData"
],
"requiredInputs": [
"fundamentals",
"marketContext.VIX",
"marketContext.SPY",
"marketContext.QQQ",
"catalystData",
"sentimentData",
"ATR",
"sector"
],
"optionalInputWarnings": []
},
"technicalIndicators": {
"adx": 78.57,
"atr": {
"atr": 6.1657,
"rule": "ATR / current price; lower volatility scores higher",
"score": 4,
"atr_pct": 4.05
},
"cci": {
"rule": "Cursor_18.24 CCI bands",
"level": "平衡",
"score": 6,
"value": 43.91
},
"cmf": {
"rule": "Cursor_18.24 CMF bands",
"level": "輕微流入",
"score": 6,
"value": 0.1274
},
"kdj": {
"d": 61.1,
"j": 18.19,
"k": 46.8,
"rule": "Cursor_18.24 K/D cross",
"score": 0,
"signal": "死叉"
},
"mfi": {
"rule": "Cursor_18.24 MFI bands",
"level": "平衡",
"score": 6,
"value": 57.65
},
"obv": {
"rule": "Cursor_18.24 recent_slope vs previous_slope",
"score": 6,
"trend": "有流入",
"value": 15242700,
"recentSlope": 295650,
"previousSlope": 985220
},
"rsi": 64.27,
"sar": {
"rule": "Cursor_18.24 Parabolic SAR",
"score": 8,
"trend": "上升",
"value": 150.6675,
"position": "SAR喺價下",
"distancePct": 0.98,
"previousTrend": "上升"
},
"ma50": 131.2764,
"macd": {
"macd": 6.772963828418511,
"trend": "中性偏多",
"signal": 7.0536812802088,
"histogram": -0.28071745179028884
},
"vwap": {
"rule": "Cursor_18.24 VWAP 20D consecutive close",
"score": 10,
"value": 146.552,
"position": "連續5日>VWAP",
"consecutiveAbove": 19
},
"volume": {
"rule": "Cursor_18.24 volume ratio",
"level": "空升",
"ratio": 0.62,
"score": 2,
"avgVolume": 2353670,
"currentVolume": 1456900
},
"derived": {
"ma20": 146.6695,
"ma50": 131.2764,
"prevClose": 153.6,
"avgVolume10": 2113580,
"avgVolume20": 2353670,
"changePercent": -0.94,
"avgVolumeForScore": 2353670
},
"ma_cross": {
"ma20": 146.6695,
"ma50": 131.2764,
"rule": "Cursor_18.24 MA20/MA50 cross",
"cross": "多頭",
"score": 4,
"prevMa20": 145.1085,
"prevMa50": 130.5006,
"spreadPct": 11.73,
"isVolumeBreakout": false
},
"bollinger": {
"lower": 130.4113,
"upper": 162.9277,
"position": "上半部"
},
"rsi_short": 47.96,
"macd_short": {
"macd": 0,
"trend": "中性",
"signal": 0,
"histogram": 0
},
"volume_ratio": {
"ratio": 0.62
}
}
}
Raw metrics JSON
{
"close": 152.16,
"volume": 1456900,
"changePercent": -0.94
}
Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank provides research support only and does not provide financial advice or buy/sell recommendations.